BioCentury
ARTICLE | Product Development

Reviving CETP

Roche, Merck data raise hopes for CETP inhibition for cholesterol lowering

September 12, 2011 7:00 AM UTC

Evidence is accumulating that the next generation of CETP inhibitors may be able to avoid the off-target effects that doomed Pfizer Inc.'s torcetrapib.

Roche reported Phase IIb data in late August showing its dalcetrapib increased HDL without raising blood pressure, inflammatory markers or imaging markers correlated with vascular harm. And Merck & Co. Inc. reported similar blood pressure data for its anacetrapib last year (see BioCentury, Nov. 22, 2010)...